Amwill Health

Why is Amwill Health Care Ltd falling/rising?

As of 01-Sep, Amwill Health Care Ltd's stock price is at 43.50, down 0.46%. This decline follows a trend reversal after three days of gains, with reduced trading activity and a significant drop in investor participation contributing to its current volatility.

As of 01-Sep, Amwill Health Care Ltd's stock price is falling, currently at 43.50, reflecting a change of -0.2 (-0.46%). This decline follows a trend reversal after three consecutive days of gains. The stock has shown erratic trading patterns, having not traded on one day out of the last twenty, which may contribute to its volatility. Additionally, there has been a significant drop in investor participation, with delivery volume on 31 August falling by 78.99% compared to the five-day average. While the stock's price is higher than its 20-day, 50-day, 100-day, and 200-day moving averages, it remains lower than the 5-day moving average, indicating a short-term weakness. Overall, these factors suggest a combination of reduced trading activity and investor interest, leading to the stock's current decline.

What does Amwill Health do?

Amwill Health Care Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2017 and transitioned to a Public Limited Company in 2024. It currently has no reported sales or profit, with a market cap of INR 87 Cr and a P/E ratio of 8.00.

Overview:<BR>Amwill Health Care Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Amwill Health Care Ltd was originally incorporated on August 21, 2017, under the name 'Amwill Health Care Private Limited'. The company transitioned to a Public Limited Company, receiving a fresh Certificate of Incorporation on January 25, 2024. There is no sales or profit data reported for any specific quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 87 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 8.00<BR>Industry P/E: 37<BR>Dividend Yield: 1.15%<BR>Debt-Equity: -0.59<BR>Return on Equity: 14.17%<BR>Price-to-Book: 1.08<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Amwill Health?

Amwill Health's peers include Asston Pharmaceu, Veerhealth Care, Denis Chem Lab, and others, with varying management and growth risks. Veerhealth Care leads in 1-year returns at 157.30%, while Denis Chem Lab has the lowest at -24.43%, with Amwill Health at -21.64%.

Peers: The peers of Amwill Health are Asston Pharmaceu, Veerhealth Care, Denis Chem Lab, Mercury Labs, Sunil Healthcare, Vineet Laborator, Samrat Pharma, Onyx Biotec, Sotac Pharma, and Zenith Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amwill Health, while Good management risk is found at Denis Chem Lab, and Average management risk is present at Asston Pharmaceu, Mercury Labs, and Samrat Pharma, and the rest. Below Average management risk is noted at Veerhealth Care, Sunil Healthcare, Vineet Laborator, Onyx Biotec, Sotac Pharma, and Zenith Drugs. In terms of Growth, Good growth is seen at Veerhealth Care and Sunil Healthcare, while Average growth is found at Amwill Health, and Below Average growth is present at Asston Pharmaceu, Denis Chem Lab, Mercury Labs, Vineet Laborator, Samrat Pharma, Onyx Biotec, Sotac Pharma, and Zenith Drugs. For Capital Structure, Excellent capital structure is noted at Denis Chem Lab and Mercury Labs, while Average capital structure is found at Asston Pharmaceu, Onyx Biotec, and Sotac Pharma, and Below Average capital structure is observed at Sunil Healthcare, Vineet Laborator, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Veerhealth Care at 157.30%, while the peer with the lowest 1-year return is Denis Chem Lab at -24.43%. Amwill Health's 1-year return is -21.64%, which is higher than Denis Chem Lab's but lower than Veerhealth Care's. Additionally, Mercury Labs, Samrat Pharma, and Zenith Drugs have negative six-month returns.

How big is Amwill Health?

As of 31st August, Amwill Health Care Ltd has a market capitalization of 87.00 Cr, classifying it as a Micro Cap company, with no valid financial data available for net sales or net profit for the latest four quarters. The balance sheet as of March 2026 shows Shareholder's Funds of 80.58 Cr and Total Assets of 86.40 Cr.

As of 31st August, <BR><BR>Market Cap: Amwill Health Care Ltd has a market capitalization of 87.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for net sales or net profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 80.58 Cr and Total Assets valued at 86.40 Cr.

Which are the latest news on Amwill Health?

When is the next results date for Amwill Health Care Ltd?

The next results date for Amwill Health Care Ltd is 30 May 2026.

The next results date for Amwill Health Care Ltd is scheduled for 30 May 2026.

Is Amwill Health overvalued or undervalued?

As of November 7, 2025, Amwill Health is considered undervalued with a PE ratio of 9.06 and strong return metrics, making it an attractive investment compared to peers like Sun Pharma and Dr Reddy's Labs.

As of 7 November 2025, Amwill Health's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 9.06, an EV to EBIT of 7.64, and an EV to EBITDA of 7.34. These ratios suggest that Amwill Health is trading at a discount compared to its peers in the pharmaceuticals and biotechnology sector.<BR><BR>In comparison, Sun Pharma is considered expensive with a PE ratio of 35.17, while Dr Reddy's Labs is attractive with a PE ratio of 17.43. This peer comparison highlights Amwill Health's favorable valuation position. Additionally, the company's return metrics are strong, with a ROCE of 18.23% and a ROE of 14.68%, further supporting the undervaluation narrative. Despite recent stock performance lagging behind the Sensex, the overall valuation suggests a compelling investment opportunity in Amwill Health.

How has been the historical performance of Amwill Health?

Amwill Health's historical performance shows fluctuating financial metrics, with net sales rising to 43.95 Cr in Mar'24 before declining to 40.58 Cr in Mar'25. Despite growth in total assets and improved cash flow, profitability metrics such as operating profit and profit after tax decreased in the latest fiscal year.

Answer:<BR>The historical performance of Amwill Health shows a fluctuating trend in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Amwill Health's net sales increased from 27.61 Cr in Mar'22 to 43.95 Cr in Mar'24, before declining to 40.58 Cr in Mar'25. Total operating income followed a similar pattern, rising to 43.95 Cr in Mar'24 and then decreasing to 40.58 Cr in Mar'25. The total expenditure also rose from 23.95 Cr in Mar'22 to 28.93 Cr in Mar'25. Operating profit, excluding other income, peaked at 16.67 Cr in Mar'24 but fell to 11.65 Cr in Mar'25. Profit before tax showed a similar decline from 16.76 Cr in Mar'24 to 11.90 Cr in Mar'25, while profit after tax decreased from 12.50 Cr to 10.73 Cr in the same period. The company's total assets grew significantly from 12.29 Cr in Mar'23 to 71.26 Cr in Mar'25, indicating a strong increase in shareholder's funds, which rose to 69.22 Cr by Mar'25. Cash flow from operating activities improved to 5.00 Cr in Mar'25, contrasting with a negative cash flow of -3.00 Cr in Mar'24. Overall, while Amwill Health experienced growth in assets and operating cash flow, its profitability metrics showed a decline in the most recent fiscal year.

Who are the top shareholders of the Amwill?

The top shareholders of Amwill include promoter Anand Gandhi with 31.64%, two Foreign Institutional Investors holding 1.16%, and public shareholder Varun Krishnavtar Kabra with 2.86%. Individual investors own 21.14% of the shares, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Amwill include the promoters, who hold the majority of the shares. The promoter with the highest holding is Anand Gandhi, owning 31.64% of the company. Additionally, there are two Foreign Institutional Investors (FIIs) that collectively hold 1.16%. The highest public shareholder is Varun Krishnavtar Kabra, with a stake of 2.86%. Individual investors also hold a significant portion, accounting for 21.14% of the shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

Has Amwill declared dividend?

No Dividend History Available